Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Richard A. J. Janssen"'
High-throughput 3D microvessel-on-a-chip model to study defective angiogenesis in systemic sclerosis
Autor:
Bart Kramer, Claudio Corallo, Angelique van den Heuvel, Justin Crawford, Thomas Olivier, Edo Elstak, Nicola Giordano, Paul Vulto, Henriette L. Lanz, Richard A. J. Janssen, Michela A. Tessari
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract In early systemic sclerosis (Scleroderma, SSc), the vasculature is impaired. Although the exact etiology of endothelial cell damage in SSc remains unclear, it is hypothesized that endothelial to mesenchymal transition (EndoMT) plays a key ro
Externí odkaz:
https://doaj.org/article/b86b2506caae477e830bdb7df0ff544d
Autor:
Claudia Beaurivage, Auste Kanapeckaite, Cindy Loomans, Kai S. Erdmann, Jan Stallen, Richard A. J. Janssen
Publikováno v:
Scientific Reports, Vol 10, Iss 1, Pp 1-16 (2020)
Abstract Inflammatory bowel disease (IBD) is a complex multi-factorial disease for which physiologically relevant in vitro models are lacking. Existing models are often a compromise between biological relevance and scalability. Here, we integrated in
Externí odkaz:
https://doaj.org/article/5ee09f4d5dd6420bbe0cfc533c9d9934
Publikováno v:
Molecular and Cellular Biology, 23, 5, pp. 1786-97
Molecular and Cellular Biology, 23, 1786-97
Molecular and Cellular Biology, 23, 1786-97
Item does not contain fulltext The down-regulation of the high-molecular-weight isoforms of tropomyosin (TM) is considered to be an essential event in cellular transformation. In ras-transformed fibroblasts, the suppression of TM is dependent on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e20e45cab4003c413d5c1ce68bff042
https://pubmed.ncbi.nlm.nih.gov/12588996
https://pubmed.ncbi.nlm.nih.gov/12588996
Publikováno v:
Cancer immunology, immunotherapy : CII. 38(1)
To induce better stimulation of T cells during recombinant interleukin-2 (rIL-2) therapy of renal cell carcinoma patients, pretreatment with low-dose CD3 monoclonal antibody (mAb) has been proposed. However, in our clinic, such a treatment did not in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23679c1936171ce2c145878cec83df53
https://pubmed.ncbi.nlm.nih.gov/8299119
https://pubmed.ncbi.nlm.nih.gov/8299119
Autor:
Richard A. J. Janssen, Jan Buter, Elske Straatsma, Agnes A. Heijn, Dirk Th. Sleijfer, Elisabeth G. E. de Vries, Nanno H. Mulder, T. Hauw The, Lou de Leij
Publikováno v:
Cancer immunology, immunotherapy : CII. 36(3)
The effect of subcutaneous recombinant interleukin-2 (rIL-2) therapy on the “activation status” of peripheral blood lymphocytes (PBL) of 17 renal cell carcinoma patients was investigated in a longitudinal study. The expression of the activation m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9a22c8dc7f49d8e4521c33462660907
https://pubmed.ncbi.nlm.nih.gov/8439981
https://pubmed.ncbi.nlm.nih.gov/8439981
Autor:
Frank Schwede, Daniela Bertinetti, Carianne N Langerijs, Michael A Hadders, Hans Wienk, Johanne H Ellenbroek, Eelco J P de Koning, Johannes L Bos, Friedrich W Herberg, Hans-Gottfried Genieser, Richard A J Janssen, Holger Rehmann
Publikováno v:
PLoS Biology, Vol 13, Iss 1, p e1002038 (2015)
The second messenger cAMP is known to augment glucose-induced insulin secretion. However, its downstream targets in pancreatic β-cells have not been unequivocally determined. Therefore, we designed cAMP analogues by a structure-guided approach that
Externí odkaz:
https://doaj.org/article/53ea691117ff4f0aada85ec8fd78efc2